Nova Reports Strong Revenue Growth In Q2, Announces Q3 Outlook

Nova Ltd. (NVMI) reported Q2 total revenue of $254.9 million versus $219.9 million a year earlier. Net income was $75.0 million, or $2.20 per diluted share, versus $68.3 million, or $2.14. Adjusted net income was $86.5 million, or $2.51. For Q3, it expects revenue of $277 million to $287 million and EPS $2.46 to $2.61 (adjusted $2.70 to $2.85).

Original reporting
Published Aug 6, 2026, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$NVMI
Bullish
medium confidence
Mentioned
$NVMI
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$NVMIBullishMed
01

Why it matters

The combination of higher Q2 revenue and explicit Q3 outlook is a direct driver of near-term trading, especially for traders trading earnings momentum and guidance credibility.

02

Market read

This is a straightforward earnings-and-guidance catalyst with quantified revenue and EPS ranges for the next quarter.

03

What to watch

Without consensus comparisons, traders should scrutinize the implied growth rate from Q2 to the Q3 revenue range and the gap between GAAP and adjusted earnings for quality of earnings.

Relevance 8/10Novelty 8/10Timing: pre-market today, ahead of the regular-session reaction to Q2 results and Q3 guidance

Background

Nova Ltd. released Q2 financial results and provided Q3 revenue and earnings guidance ranges.

Company-level read

Ticker impact

$NVMIBullishMedium confidence
Context

Nova Ltd. reported Q2 revenue of $254.9M versus $219.9M and issued Q3 revenue and EPS guidance for the next quarter.

Expected impact

Likely upward bias at the open if guidance is viewed as credible versus Street expectations, despite the pre-market dip.

Evidence & confidence

The article provides both reported results (revenue, net income, adjusted EPS) and forward guidance ranges, which typically drive same-day repricing. However, it does not state consensus or whether the pre-market move reflects guidance vs expectations.

Market effects

Signals demand strength and margin/profitability momentum for Nova’s device/customer segments, which can influence sentiment toward similar semiconductor/communications suppliers.

Limited direct regional spillover; the catalyst is company-specific.

Moderate, as it is a single-company earnings and guidance update without broader macro/regulatory linkage.

Counterpoint

The pre-market decline suggests the market may be discounting the quarter or focusing on whether guidance midpoint is below expectations or implies slower growth than desired.

Key entities

  • Nova Ltd.

    Reported Q2 revenue growth and announced Q3 revenue and EPS guidance.

  • NVMI

    Nova Ltd.’s US-listed equity referenced in the article.

Related articles

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.

$NVMIMed

Nova WMC™ Expanding Adoption Across the Most Advanced Packaging Processes

Nova (NASDAQ: NVMI) said a leading global foundry customer selected its Nova WMC™ platform as tool-of-record for multi-layer measurement in advanced packaging. The company expects the win to support multiple production flows and notes accelerating WMC™ adoption across memory and foundry customers. Nova cited modular design and nanometer-level large-area scanning throughput.

$TSEMMed

Mon: TASE suffers biggest falls since October 8, 2023

Israel’s Tel Aviv Stock Exchange fell sharply after Iran halted talks with the US over escalation in Lebanon, according to the report. The Tel Aviv 35 Index dropped 4.21% to 4,268.02 and Tel Aviv 125 fell 4.31% to 4,239.39. Turnover was NIS 5.91b in equities and NIS 6.31b in bonds. Tower Semiconductor led losses (-13.99%).

$WHWKMed

Whitehawk Therapeutics, Inc. (WHWK): Results of Operations and Financial Condition

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 whwk-ex99_1.htm EX-99.1 EX-99.1 PRESS RELEASE Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cas

$TPGMed

TPG Q2 Deep Dive: Asset Growth, Fundraising Momentum, and AI

TPG (NASDAQ: TPG) reported Q2 CY2026 results. Revenue rose 24.7% year over year to $610.4 million, beating the $566.5 million analyst estimate. Non-GAAP EPS was $0.69 versus $0.59. Management cited higher management fees, capital markets activity, and $16 billion raised in the quarter. CFO Axel Andre was appointed, and TPG expects continued fundraising and fee growth.